This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Abnormalities of hair growth such as eyelash hypertrichosis¹ and telogen effluvium² may result from use of interferon alfa (IFN-). In addition, localized injection site reactions may include vasculitis and cutaneous necrosis.³ We report subcutaneous injection site alopecia in 3 patients receiving interferon alfa-2b for chronic hepatitis C as part of an institutional review board–approved treatment protocol. To our knowledge, this side effect of interferon alfa-2b is previously unreported.

Report of Cases

Case 1

A 45-year-old man presented with asymptomatic hair loss on his thighs limited to sites of subcutaneous interferon alfa-2b injections which he had begun 3 months earlier (5 x10⁶ U 7 times a week for 4 weeks, followed by 5 x10⁶ U 3 times a week). There was no history of trauma in the affected areas as a result of work or hobbies. He had no similar hair loss elsewhere on his body. The patient was otherwise healthy except for . . . [Full Text of this Article]

Case 2

Case 3

Comment